NASDAQ · Biotechnology

Amylyx Pharmaceuticals, Inc. (AMLX) Stock

$28.14 +3.46% NASDAQ: AMLX Healthcare

Valuation

MetricValue
Price$28.14
Market Cap$3.13B
P/E Ratio-19.71
P/B Ratio12.92
P/S Ratio0.00
EPS (TTM)$-1.53
52-Week High$41.14
52-Week Low$10.83
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-52.92%
ROA-57.49%
ROCE-66.60%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio14.09

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$22.0M$381.0M$87.0M$0
Operating Profit$-83.0M$-201.0M$39.0M$-315.0M$-153.0M
Net Profit$-88.0M$-198.0M$49.0M$-302.0M$-145.0M
EPS$-1.52$-2.98$0.70$-4.43$-1.53
Op Margin—-905.7%10.2%-360.2%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$106.0M$391.0M$517.0M$194.0M$333.0M
Total Liabilities$257.0M$51.0M$84.0M$29.0M$27.0M
Cash$50.0M$63.0M$170.0M$77.0M$227.0M
Borrowings$0$6.0M$4.0M$2.0M$6.0M

Latest News

Post-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsight PR Newswire · Jul 7, 2026 Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data? Insider Monkey · Jun 30, 2026 Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026 Business Wire · Jun 23, 2026 Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape MarketBeat · Jun 10, 2026 Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026 Business Wire · Jun 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-75.0M$-180.0M$12.0M$-168.0M$-123.0M
Investing Cash Flow$-47.0M$-242.0M$91.0M$75.0M$14.0M
Financing Cash Flow$-2.0M$-1.0M$-3.0M$-2.0M$-3.0M
Net Cash Flow$37.0M$13.0M$108.0M$-92.0M$149.0M
Free Cash Flow$-75.0M$-182.0M$11.0M$-168.0M$-123.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.33
EV / EBITDA-20.34
FCF Yield-4.10%
Quick Ratio12.12
Interest Coverage0.00
Return 1Y268.79%
Return 3Y60.09%
Return 5Y—

Ownership

Insiders Held7.89%
Institutions Held105.37%
Institutions Float Held114.39%
Institutional HolderSharesReport Date
FMR, LLC16,630,5412026-03-31
Blackrock Inc.8,828,8362026-03-31
Perceptive Advisors Llc8,284,8822026-03-31
TCG Crossover Management, LLC6,243,8122026-03-31
Commodore Capital Lp5,650,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. is led by CEO Joshua Cohen, employs 123 people, headquartered in US, publicly traded since 2022.

Amylyx Pharmaceuticals, Inc. (AMLX) stock trades at $28.14 with a market capitalization of $3.13B. The stock is valued at a price-to-earnings (P/E) ratio of -19.71, price-to-book of 12.92, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $10.83 and $41.14, and currently trades 31.6% below its 52-week high.

On profitability, Amylyx Pharmaceuticals, Inc. generates a return on equity (ROE) of -52.92%, return on capital employed of -66.60%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.67 +1.27%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides